Ex Vivo Expanded Erythroblast-Transplantation for patient with critical limb ischemia
- Conditions
- Peripheral Arterial Disease (PAD) , Buerger disease, and arteritis associated with collagen diseases (Fontaines stage: III and IV)
- Registration Number
- JPRN-UMIN000021374
- Lead Sponsor
- EVEETA Study Group
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 11
Not provided
1. Patients with the expected rest of their life less than 1 year 2. Patients with drug dependence during the past 3 months 3. Patients with malignant evidence of malignant disorder during the past 5 years 4. Patients with poorly controlled diabetes mellitus accompanied with proliferative retinopathy 5. Patients with polycythemia; Hematcrit >55%(male), >50%(female) 6. Patients without informed consent 7. Pregnant or possibly pregnant females 8. Patients with acute myocardial infarction, unstable angina, myocarditis, or cerebral infarction during the past 1 month 9. Patients with active infection including Treponema pallidum, or positive test for Human Immunodeficiency Virus (HIV), Hepatitis B Virus (HBV) and Hepatitis C Virus (HCV) 10. Patients with history of allergy for antibiotics 11. Patients with anemia or thrombocytopenia 12. Patients judged inappropriate for this study by phisician 13. Patients without agreement for including in this study
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method improvement of skin perfusion pressure level at ischemic leg 1 month after EVEETA
- Secondary Outcome Measures
Name Time Method